View on GitHub

Added entries:

  • (FDA) ABL1 p.T315I and sensitivity to ponatinib for patients with acute lymphoid leukemia.
  • (FDA) ABL1 p.T315I and sensitivity to ponatinib for patients with chronic myeloid leukemia.
  • (FDA) BCR::ABL1 and sensitivity to ponatinib in combination with chemotherapy for patients with acute lymphoid leukemia.
  • (FDA) BCR::ABL1 and sensitivity to ponatinib for patients with acute lymphoid leukemia.

Revised entries:

  • The therapeutic strategy for two records with ROS inhibition were changed to ROS1 inhibition
  • MRE11A somatic variants and sensitivity to enzalutamide in combination with talazoparib for patients with prostate cancer was updated to have the gene symbol be MRE11

All records were also updated to have a _deprecated field, which is a boolean value to hide the record from appearing on https://moalmanac.org.